Company / Return on Assets (ROA)
Kymera Therapeutics, Inc. Return on Assets (ROA) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-17.9%
FY2025
5-year range
-25.7% / -6.8%
FY2021-FY2025
Trend
+22.0%
vs FY2024
Sector context
#97 of 213
Health Care
What the data says
At -17.9%, Kymera Therapeutics, Inc.'s return on assets (roa) ranks #97 of 213 in the Health Care sector. Return on Assets (ROA) has increased for 3 consecutive years, from -25.7% in FY2022 to -17.9% in FY2025.
Based on SEC 10-K filings.
-17.9% in FY2025 with a 5-year CAGR of -9.4%.
Improved from -25.5% to -17.9% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +7.8pp
- 5-Year Change
- -9.4pp
- 10-Year Change
- -
Sector benchmark
#97 of 213 in Health CareTop 46% of 213This company -17.9% Sector average -24.2%
▼
+26.1% above sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s return on assets (roa) has grown for 3 consecutive years.
- In FY2025, return on assets (roa) increased 22.0% year-over-year.
- Currently 6.3pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -17.9% | +22.0% |
| FY2024 | -22.9% | +10.3% |
| FY2023 | -25.5% | +0.6% |
| FY2022 | -25.7% | -276.9% |
| FY2021 | -6.8% | +19.6% |
| FY2020 | -8.5% | +76.0% |
| FY2019 | -35.3% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026